Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sube Banerjee

Showing results (201-210 of 215) with videos related to

Pageof 22
Sort By:
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
BMJ Open|December 25, 2013
Improving the identification of people with dementia in primary care: evaluation of the impact of primary care dementia coding guidance on identified prevalencePaul Russell, Sube Banerjee, Jen Watt, et al.
The Lancet. Neurology|October 31, 2015
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analysesRobert Howard, Rupert McShane, James Lindesay, et al.
Alzheimer'S & Dementia (New York, N. Y.)|May 5, 2022
A cohort study of the impact of COVID-19 on the quality of life of people newly diagnosed with dementia and their family carersBen Hicks, Sanna Read, Bo Hu, et al.
Lancet (London, England)|August 3, 2020
Dementia prevention, intervention, and care: 2020 report of the Lancet CommissionGill Livingston, Jonathan Huntley, Andrew Sommerlad, et al.
Lancet (London, England)|August 3, 2024
Dementia prevention, intervention, and care: 2024 report of the Lancet standing CommissionGill Livingston, Jonathan Huntley, Kathy Y Liu, et al.
The New England Journal of Medicine|March 9, 2012
Donepezil and memantine for moderate-to-severe Alzheimer's diseaseRobert Howard, Rupert McShane, James Lindesay, et al.
Trials|July 28, 2009
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCTRob Jones, Bart Sheehan, Patrick Phillips, et al.
Age and Ageing|January 26, 2024
Long-term impact of the COVID-19 pandemic on the quality of life of people with dementia and their family carersSanna Read, Ben Hicks, Emily Budden, et al.
Age and Ageing|November 16, 2020
Mild cognitive impairment: the Manchester consensusRoss A Dunne, Dag Aarsland, John T O'Brien, et al.
Pageof 22

Showing results (201-210 of 215) with videos related to

Sort By:
Pageof 22
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
BMJ Open|December 25, 2013
Improving the identification of people with dementia in primary care: evaluation of the impact of primary care dementia coding guidance on identified prevalencePaul Russell, Sube Banerjee, Jen Watt, et al.
The Lancet. Neurology|October 31, 2015
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analysesRobert Howard, Rupert McShane, James Lindesay, et al.
Alzheimer'S & Dementia (New York, N. Y.)|May 5, 2022
A cohort study of the impact of COVID-19 on the quality of life of people newly diagnosed with dementia and their family carersBen Hicks, Sanna Read, Bo Hu, et al.
Lancet (London, England)|August 3, 2020
Dementia prevention, intervention, and care: 2020 report of the Lancet CommissionGill Livingston, Jonathan Huntley, Andrew Sommerlad, et al.
Lancet (London, England)|August 3, 2024
Dementia prevention, intervention, and care: 2024 report of the Lancet standing CommissionGill Livingston, Jonathan Huntley, Kathy Y Liu, et al.
The New England Journal of Medicine|March 9, 2012
Donepezil and memantine for moderate-to-severe Alzheimer's diseaseRobert Howard, Rupert McShane, James Lindesay, et al.
Trials|July 28, 2009
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCTRob Jones, Bart Sheehan, Patrick Phillips, et al.
Age and Ageing|January 26, 2024
Long-term impact of the COVID-19 pandemic on the quality of life of people with dementia and their family carersSanna Read, Ben Hicks, Emily Budden, et al.
Age and Ageing|November 16, 2020
Mild cognitive impairment: the Manchester consensusRoss A Dunne, Dag Aarsland, John T O'Brien, et al.
Pageof 22